Sharemaestro Newsreel

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Cadrenal Therapeutics (NASDAQ: CVKD) reported a Q2 2026 net loss of $3.3 million, narrowing from $3.7 million in Q2 2025, and operating expenses decreased to $3.3 million. The company announced positive Phase 2 data for CAD-1005, showing over a 25% absolute reduction in thrombotic …

Ardelyx (ARDX) Is Down 19.1% After ESOP Shelf Filing And Higher 2026 Product Revenue Guidance

Ardelyx (ARDX) experienced a 19.1% stock drop following a US$36 million shelf registration for an ESOP and its Q2 earnings report. Despite a net loss, the company raised its 2026 IBSRELA revenue guidance to US$350–370 million, while reiterating XPHOZAH revenue expectations. This move signals …

X4 Pharma chairman Craig R. sells $210,829 in shares

X4 Pharmaceuticals' Executive Chairman, Craig R., sold 47,436 shares of the company's common stock for $210,829 to cover personal income tax obligations related to a restricted stock unit award. Despite this sale, analysts remain bullish on X4 Pharma, with Wells Fargo and Leerink initiating …

Polaryx Therapeutics (PLYX) cuts losses as cash rises to $11.5M

Polaryx Therapeutics, a clinical-stage biotech company, reported a narrowed net loss of $1.4 million for Q2 2026 and $3.9 million for the first half of 2026, alongside a significant increase in cash and cash equivalents to $11.5 million, primarily due to a $10 million …

Caribou Biosciences reports Q2 2026 results: $1.5M licensing revenue, $24.3M GAAP net loss

Caribou Biosciences reported its Q2 2026 financial results, showing $1.5 million in licensing revenue and a GAAP net loss of $24.3 million. The company holds $113.8 million in cash and expects these funds to support operations through the end of 2027. Business highlights include …

Caribou Biosciences Q2 Results: Net loss narrows to $24.3 million

Caribou Biosciences reported a narrowed net loss of $24.3 million in Q2 2026, significantly improving from $54.1 million in Q2 2025, beating EPS estimates. This was primarily due to a sharp decline in operating expenses and cost-cutting measures. However, quarterly sales missed analyst forecasts, …

Caribou Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Caribou Biosciences, Inc. has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement from Reuters, indicating that a full report is available to subscribers of TradingView.

BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary

BioAtla, Inc. reported second-quarter 2026 results, showing revenue of $6.5 million and diluted EPS of $0.27, a significant improvement from the prior year's net loss and zero revenue. The company is undergoing a strategic review to maximize shareholder value, pausing clinical development, and implementing …

Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake

Bleichroeder entities, led by Bleichroeder LP and Andrew Gundlach, have reported a 9.99% equity stake in Cellectar Biosciences (CLRB), amounting to 808,300 common shares. Bleichroeder LP, a registered investment adviser, holds these shares for various advisory clients, granting them sole voting and dispositive power …

Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations

Aktis Oncology (NASDAQ:AKTS) recently reported its earnings, meeting the consensus estimate for EPS at ($0.44) and surpassing revenue expectations with $3.38 million. Despite the positive earnings surprise, the stock traded down 0.9% to $23.79, giving the company a market capitalization of approximately $1.27 billion. …

PolyPid (PYPD) investors disclose up to 13.4% beneficial stake via complex structure

A group of related investors, led by Xenia Venture Capital Limited, has filed an amended Schedule 13G/A for PolyPid Ltd. (PYPD), disclosing a beneficial ownership of up to 13.4% of the company's Ordinary Shares. The complex ownership structure involves Rodney Hodges, Geneva Holding Company …

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners has updated its coverage on NeOnc Technologies Holdings, Inc. (NTHI) for 2Q26, highlighting significant clinical advancements for its lead programs NEO100 and NEO212. NEO100 achieved a positive Phase 2a readout with strong progression-free survival and overall survival rates, moving towards a …

Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares

Mineralys Therapeutics insider David Rodman has filed a Form 144, indicating his intention to sell up to 14,056 shares of common stock through Merrill Lynch on or after August 13, 2026. The aggregate market value of the planned sale is $372,187.00. These shares originate …

GH Research PLC (GHRS) director receives 2,202 options at $0.025 strike

GH Research PLC director Dermot John Hanley was granted 2,202 share options with an exercise price of $0.025 per share. These options vested immediately but are not exercisable until August 11, 2028, and will expire on August 11, 2033. Following this transaction, Hanley directly …

GH Research PLC (GHRS) director receives 2,202 fully vested share options

GH Research PLC director Duncan Moore was granted 2,202 fully vested share options on August 11, 2026, with an exercise price of $0.0250 per ordinary share and an expiration date of August 11, 2033. Although immediately vested, these options are not exercisable until August …

GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer

GH Research PLC (GHRS) director Michael Forer received two grants of share options totaling 102,202 Ordinary Shares, both with an exercise price of $0.0250 per share and expiring on August 11, 2033. One grant of 2,202 options is immediately vested but not exercisable until …

ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

The Rosen Law Firm announces a class action lawsuit on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026. Investors who bought shares during this period are encouraged to secure counsel before the October 5, …

RYTM (RYTM) insider plans Form 144 sale of option and RSU shares

An insider at Rhythm Pharmaceuticals (RYTM) has filed a Form 144 indicating a proposed sale of 75,834 common shares through Morgan Stanley Smith Barney LLC. This total includes 56,601 shares from stock option exercises dated August 13, 2026, and 19,233 shares from Restricted Stock …

Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss

Elicio Therapeutics reported a net loss of $20.0 million for the first half of 2026 and faces substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into Q1 2027. The company's lead Phase 2 …

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Form 8K Mink Therapeutics Inc For: 13 August By Investing.com

This article reports that Mink Therapeutics Inc. filed a Form 8K on August 13. The company's stock symbol INKT is mentioned, showing a slight increase of 2.45%. No further details about the content of the Form 8K are provided.

Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal

Kyntra Bio: Q2 Earnings Snapshot

ARS PHARMACEUTICALS ($SPRY) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Total Revenue: $33.7 million in Q2 2026, reflecting a combination of net product, collaboration, and supply revenue. US Net Product Revenue: $26.2 million for the second quarter. Total Operating Expenses: $95.1 million in Q2 2026, including $12.8 million …

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

Tempest Therapeutics announced a collaboration with Senlang Biotechnology to advance its TPST-4003 in vivo CAR-T product candidates, targeting first patient dosing in late 2026 and initial clinical data in early 2027. The company also appointed Drake Richey and Dr. John Yee to its Board …

NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings

Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins

Edesa Biotech (EDSA) reported a net loss of $5.4 million for Q3 2026, an increase from $1.7 million in the prior year, primarily due to rising operating expenses from its Phase 2 EB06 vitiligo study. The company is beginning site activation for this study …

Elicio Therapeutics: Q2 Earnings Snapshot

Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results

Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS

* Candel Therapeutics press release [https://seekingalpha.com/pr/20618191-candel-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate] (CADL [https://seekingalpha.com/symbol/CADL]): Q2 GAAP EPS of -$0.52 misses by $0.29. * Cash and cash equivalents of $201.6 million, as of June 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q1 2028, …

Alpha Cognition reports Q2 revenue growth, narrows loss By Investing.com

Alumis Inc. (ALMS) reports $235M loss but ends quarter with $502M cash

Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue

Assembly Biosciences (ASMB) boosts cash to $320M and narrows loss

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026